Mutabon Forte (Amitriptyline Hydrochloride, Perphenazine)

Amitriptyline blocks the reuptake of norepinephrine and serotonin, raising their levels in the brain and improving mood. Perphenazine blocks dopamine D2 receptors, reducing psychotic symptoms such as hallucinations and delusions. Together they target two different neurotransmitter systems involved in depression and psychosis.

The dosage of Mutabon Forte is individualized. A qualified prescriber determines the appropriate dose based on the patient’s clinical condition, response to therapy and any relevant safety considerations. No fixed regimen is provided in public information.

Safety data for Mutabon Forte in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a healthcare professional.

To request Mutabon Forte, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mutabon Forte uniquely combines a tricyclic antidepressant (amitriptyline) with a typical antipsychotic (perphenazine). Compared with newer atypical antipsychotic‑antidepressant combos, it may have a higher anticholinergic burden and different side‑effect profiles, but it can be effective for patients who respond well to tricyclics and need strong dopamine blockade.

Mutabon Forte should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct light to maintain potency throughout the shelf life.

Mutabon Forte is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include cardiac arrhythmias such as QT prolongation, neuroleptic malignant syndrome, severe hypotension, seizures and agranulocytosis. Patients should be monitored closely for any signs of these conditions, and immediate medical attention is required if they occur.

Mutabon Forte is contraindicated in individuals with known hypersensitivity to amitriptyline, perphenazine or any component of the formulation, as well as in patients taking monoamine oxidase inhibitors within the past 14 days. Caution is also advised for patients with uncontrolled cardiac disease, severe liver impairment or a history of seizures.